

Fine-Tuning the Care of Patients With Moderate-to-Severe Crohn's Disease Using Novel Targeted Therapies



Russell D. Cohen, MD



Uma Mahadevan, MD

MON
MAY 20

Marriott Marquis Washington, DC
Marquis Ballroom Salons 1-4

6:00 - 6:30 PM Registration & Dinner
6:30 - 7:30 PM Symposium



To register, scan the QR code or go to: www.answersincme.com/IME-62534

ENGAGE IN DISCUSSION WITH THE EXPERTS

- Welcome and Introduction
- Exploring Unmet Needs in Moderate-to-Severe Crohn's Disease (CD): The Rationale for Novel Targeted Therapies
- Acknowledging the Impact: The Latest Clinical Data for Approved JAK Inhibitors in Moderate-to-Severe CD
- Acknowledging the Impact: The Latest Clinical Data for Approved IL-23 Inhibitors in Moderate-to-Severe CD
- Individualizing Treatment Selection in Moderate-to-Severe CD: Key Factors to Consider
- Refining Personalized Care Using Novel Targeted Therapies in Moderate-to-Severe CD
- Questions and Take-Home Learnings